Market capitalization | $245.44m |
Enterprise Value | $211.22m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 27.90 |
P/S ratio (TTM) P/S ratio | 32.42 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | -55.31% |
Revenue (TTM) Revenue | $7.57m |
As a Free StocksGuide user, you can view scores for all 6,842 stocks worldwide.
4 Analysts have issued a Tvardi Therapeutics forecast:
4 Analysts have issued a Tvardi Therapeutics forecast:
Mar '25 |
+/-
%
|
||
Revenue | 7.57 7.57 |
55%
55%
|
|
Gross Profit | 5.02 5.02 |
61%
61%
|
|
EBITDA | -28 -28 |
77%
77%
|
EBIT (Operating Income) EBIT | -28 -28 |
77%
77%
|
Net Profit | -45 -45 |
63%
63%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Tvardi Therapeutics Inc is a US-based company operating in Pharmaceuticals industry. The company is headquartered in Stamford, Connecticut and currently employs 10 full-time employees. The company went IPO on 2014-01-31. Tvardi Therapeutics, Inc., formerly Cara Therapeutics, Inc., is a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting (STAT3) to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. Its product candidate, TTI-101, is in Phase 2 clinical development for the treatment of fibrosis-driven diseases, with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is an oral, small-molecule, which is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
Head office | United States |
CEO | Imran Alibhai |
Founded | 2004 |
Website | www.caratherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.